U.S. Markets closed

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.30+0.12 (+2.32%)
At close: 11:21AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.18
Open5.32
Bid4.59 x 900
Ask8.00 x 3000
Day's Range5.30 - 5.56
52 Week Range3.30 - 8.24
Volume7,448
Avg. Volume17,639
Market Cap415.107M
Beta (5Y Monthly)-0.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.35
  • IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses of $100,000 to Contact the Firm
    ACCESSWIRE

    IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / November 27, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Innate Pharma S.

  • UPCOMING DEC. 22 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against  Innate Pharma S.A. – IPHA
    GlobeNewswire

    UPCOMING DEC. 22 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Innate Pharma S.A. – IPHA

    NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) from March 10, 2020 through September 8, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Innate Pharma S.A. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Innate touted the results of their various Phase 2 trials as being within expectations; (2) Innate continued to reassure investors that they were eligible for the $100 million payment upon first dosing of Phase 3 trials; (3) Innate failed to timely disclose their renegotiations with AstraZeneca to split the $100 million payment into two $50 million payments, to be partially contingent on performance during the Phase 3 trials; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.If you wish to serve as lead plaintiff, you must move the Court no later than December 22, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter. \-------------------------------Contact:   Vik Pawar, Esq.   Pawar Law Group   20 Vesey Street, Suite 1410   New York, NY 10007   Tel: (917) 261-2277   Fax: (212) 571-0938   info@pawarlawgroup.com

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA

    NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Innate and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On October 23, 2018, Innate and AstraZeneca plc (“AstraZeneca”) announced an expansion of a pre-existing collaboration agreement between the two companies, pursuant to which AstraZeneca purchased 9.8% of a newly-issued equity stake in Innate and obtained, among other things, full oncology rights to monalizumab, a first-in-class humanized anti-NKG2A antibody.  As part of this agreement, Innate was to receive $100 million in milestone payments at the start of the first Phase 3 clinical trial for monalizumab.  Then,  on September 8, 2020, Innate issued a press release announcing, in relevant part, that Innate and AstraZeneca had amended their collaboration agreement, such that Innate “will now receive a $50 million payment upon AstraZeneca’s dosing of the first patient in the Phase 3 trial, and a $50 million payment after the interim analysis demonstrates the combination meets a pre-defined threshold of clinical activity.” On this news, Innate’s American Depositary Share (“ADS”) price fell $1.62 per share, or 26.6%, to close at $4.45 per ADS on September 8, 2020.The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.CONTACT:  Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com 888-476-6529 ext. 7980